JP2022546414A5 - - Google Patents

Info

Publication number
JP2022546414A5
JP2022546414A5 JP2022513164A JP2022513164A JP2022546414A5 JP 2022546414 A5 JP2022546414 A5 JP 2022546414A5 JP 2022513164 A JP2022513164 A JP 2022513164A JP 2022513164 A JP2022513164 A JP 2022513164A JP 2022546414 A5 JP2022546414 A5 JP 2022546414A5
Authority
JP
Japan
Prior art keywords
alkyl
independent
halo
deutherium
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546414A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048621 external-priority patent/WO2021041975A1/en
Publication of JP2022546414A publication Critical patent/JP2022546414A/ja
Publication of JP2022546414A5 publication Critical patent/JP2022546414A5/ja
Pending legal-status Critical Current

Links

JP2022513164A 2019-08-29 2020-08-28 Ｐｅｒｋ阻害ピロロピリミジン化合物 Pending JP2022546414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
US62/893,528 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (2)

Publication Number Publication Date
JP2022546414A JP2022546414A (ja) 2022-11-04
JP2022546414A5 true JP2022546414A5 (https=) 2023-08-28

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513164A Pending JP2022546414A (ja) 2019-08-29 2020-08-28 Ｐｅｒｋ阻害ピロロピリミジン化合物

Country Status (12)

Country Link
US (1) US20220356186A1 (https=)
EP (1) EP4021908A1 (https=)
JP (1) JP2022546414A (https=)
KR (1) KR20220066290A (https=)
CN (1) CN114710956A (https=)
AU (1) AU2020336975A1 (https=)
BR (1) BR112022003584A2 (https=)
CA (1) CA3152508A1 (https=)
IL (1) IL290889A (https=)
MX (1) MX2022002446A (https=)
PH (1) PH12022550491A1 (https=)
WO (1) WO2021041975A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585606A (zh) 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
JP6493218B2 (ja) * 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
ES2965081T3 (es) * 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
RS65914B1 (sr) * 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja

Similar Documents

Publication Publication Date Title
JP2022546414A5 (https=)
JP2010531345A5 (https=)
US20140011798A1 (en) Imidazopyrrolidinone compounds
US11725005B2 (en) Compositions and methods for inhibiting kinases
JP2019517487A5 (https=)
JP2013544893A5 (https=)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
TWI592157B (zh) 治療增生性疾病及其他由ｂｃｒ－ａｂｌ、ｃ－ｋｉｔ、ｄｄｒ１、ｄｄｒ２或ｐｄｇｆ－ｒ激酶活性所調節之病症之方法
BR112012017713A2 (pt) Aminopiridina, formulação farmacêutica, processo para a preparação de um derivado de aminopiridina, intermediário, e, uso de uma aminopiridina ou de uma formulação farmacêutica
JP2018529770A5 (https=)
RU2008110913A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ ГЛИКОГЕНСИНТАЗЫ 3 ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ДЕМЕНЦИИ И НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ
JP2022501429A5 (https=)
RU2003121307A (ru) (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
CA2568608A1 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
CA2803055A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
RU2017145928A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
WO2013082324A1 (en) Improved modulators of hec1 activity and methods therefor
JP2023547396A5 (https=)
US20190030009A1 (en) Compounds and compositions for the treatment of cryptosporidiosis
US20240245634A1 (en) Pcna inhibitors and egfr inhibitors for cancer treatment
CN113242736A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法
AU2017205389A1 (en) Benzothiazole amphiphiles
CA2564574A1 (en) Use of c-kit inhibitors for treating fibrosis
RU2015101211A (ru) Производное имидазопиридина, используемое для лечения сахарного диабета